Clinical trial of pirotinib for the treatment of cancer in China
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2016
Price : $35 *
At a glance
- Drugs Pirotinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 29 Mar 2016 Status changed from not yet recruiting to recruiting, as reported in a Sihuan Pharmaceutical Holdings media release.
- 18 Nov 2013 New trial record
- 10 Oct 2013 Clinical trial approval of pirotinib was accepted by the China Food and Drug Administration (CFDA), according to a Sihuan Pharmaceutical Holdings Group media release.